DADC
CORT icon

D.A. Davidson & Co’s Corcept Therapeutics CORT Stock Holding History

D.A. Davidson & Co’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-192,634
Closed -$1.25M – 2445
2016
Q3 		$1.25M Buy
192,634
+105,000
+120% +$611K 0.03% 408
2016
Q2 		$478K Sell
87,634
-60,051
-41% -$312K 0.01% 553
2016
Q1 		$691K Buy
+147,685
New +$575K 0.02% 458

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.A. Davidson & Co's CORT Position: Q4 2016 in Review

D.A. Davidson & Co sold out of Corcept Therapeutics (CORT) in Q4 2016, closing a stake of 192,634 shares — an estimated $1.25M sold.

D.A. Davidson & Co first reported a position in CORT in Q1 2016 and held it in 3 quarters. The position peaked at $1.25M in Q3 2016. 135 funds tracked by Wall St. Rank hold CORT as of Q4 2016.

  • D.A. Davidson & Co reported no remaining Corcept Therapeutics position as of Q4 2016 after selling out during the quarter.
  • D.A. Davidson & Co sold 192,634 Corcept Therapeutics shares in Q4 2016, an estimated $1.25M.
  • D.A. Davidson & Co first reported a position in Corcept Therapeutics in Q1 2016 and held it in 3 quarters.
  • D.A. Davidson & Co's Corcept Therapeutics position peaked at $1.25M in Q3 2016.
  • 135 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2016.

Based on D.A. Davidson & Co's 13F filing for Q4 2016, filed 15 Feb 2017.